Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and iPS Cell Culture Applications 

 

 

Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and iPS Cell Culture Applications

June 11, 2012 - (Fate) - “Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies. BD™ SMC4 is a patent protected, pre-formulated cocktail of small molecules for improving cellular reprogramming efficiencies and for enabling single-cell passaging and flow cytometry sorting of iPSCs in feeder cell-free and other pluripotent cell culture systems.”  Read Full Article 

 

Posted on 2-Jul-12 by Toto, Brent
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: